Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Pfizer Inc. Add to portfolio

NYA:PFE, Dec 14, 11:01 UTC

Latest NYA:PFE News

Filter your feed

Apply Filter

Wednesday, December 12


News

Global Osteonecrosis Treatment Market Report 2019-2023 Featuring Atnahs, Merck Sharp & Dohme, Mylan, Pfizer and Teva Pharmaceutical

PFE MYL

Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Osteonecrosis Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The development of stem cells is increasing to engineer advanced stem cells-based treatment that can demonstrate better efficacy and has fewer side effects than the available treatments. Market OverviewRising awareness about osteonecrosisOsteonecrosis is an idiopathic disease as it occurs without trauma and the early diagnosis increases the chances of treatment. Thus, the available treatment are expected to strongly decelerate the growth of the global osteonecrosis market. For the detailed list of factors that will drive and challenge the growth of the osteonecrosis treatment market during the 2019-2023, view this report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Mylan and Pfizer, the competitive environment is quite intense.

Read Full Details

Topics:
  • Business
  • Health

Tuesday, December 11


News

Pfizer shares fall premarket after JPMorgan downgrades to neutral

PFE

Pfizer Inc. shares slid 1.1% in premarket trade Tuesday, after JP Morgan downgraded the stock to neutral from overweight and said it's moving to the sidelines after a strong 2018. "We clearly have seen a positive shift in Pfizer's narrative, which is now focused on the re-acceleration of the company's top and bottom line growth beyond 2020 (where sales growth of ~5% is expected to exceed the group)," analyst Chris Schott wrote in a note. Further upside for the stock is likely tied to additional pipeline success or positive new launch momentum, said Schott, both of which are unlikely before 2020. Pfizer shares have gained 22.6% in 2018, while the S&P 500 has fallen 1.3%.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment
News

JP Morgan downgrades Pfizer, saying stock has moved too far, too fast: 'Moving to the sidelines'

PFE

JP Morgan downgrades Pfizer, saying stock has moved too far, too fast: 'Moving to the sidelines'. J.P. Morgan downgraded Pfizer shares to neutral from overweight on Tuesday, warning clients that the stock's rally will likely slow after climbing more than 22 percent this year. "We clearly have seen a positive shift in Pfizer's narrative, which is now focused on the re-acceleration of the company's top and bottom line growth beyond 2020," J.P. Morgan's Chris Schott said in a note. "And with further upside to shares likely tied to either additional pipeline success or positive new launch momentum (largely 2020+ events), we are moving to the sidelines."

Read Full Details

Topics:
  • Business
  • Financial

Monday, December 10


News

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

PFE

In the latest trading session, Pfizer (PFE) closed at $44.40, marking a +1.09% move from the previous day. Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be January 29, 2019. On that day, PFE is projected to report earnings of $0.64 per share, which would represent year-over-year growth of 3.23%. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Read Full Details

Topics:
  • Business
  • Financial

Friday, December 07


News

Do Hedge Funds Love Pfizer Inc. (PFE)?

PFE

Our calculations also showed that PFE isn't among the 30 most popular stocks among hedge funds. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's flagship best performing hedge funds strategy returned 6.3% year to date (through December 3rd) and outperformed the market even though it draws its stock picks among small-cap stocks. The graph below displays the number of hedge funds with bullish position in PFE over the last 13 quarters. So, let's examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

Read Full Details

Topics:
  • Business
  • Financial
News

Perigon Wealth Management LLC Raises Position in Pfizer Inc. (NYSE:PFE) – Fairfield Current

PFE

Perigon Wealth Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 202.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). In related news, major shareholder Pfizer Inc bought 55,556 shares of the stock in a transaction on Monday, October 15th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have given a buy rating to the company. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 3 EPS for the current fiscal year.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, December 04


News

Pfizer (PFE) Stock Moves -1.78%: What You Should Know

PFE

Pfizer (PFE) Stock Moves -1.78%: What You Should Know. Pfizer (PFE) closed at $45.17 in the latest trading session, marking a -1.78% move from the prior day. Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $13.73 billion, up 0.18% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $3 per share and revenue of $53.40 billion, which would represent changes of +13.21% and +1.62%, respectively, from the prior year.

Read Full Details

Topics:
  • Business
  • Financial
News

Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche

PFE AMGN +1 more PFE AMGN MRK

The "Cancer Immunotherapy Market" report has been added to ResearchAndMarkets.com's offering. Further, increasing awareness about early diagnosis and advanced personalized medicine as a part of targeted therapy is key growth driver for global Cancer Immunotherapy market over the forecast period. North America is slated to account for a share of 37.0% by 2027 in the Cancer Immunotherapy market. Pfizer, Merck, Amgen and Roche are some of the prominent players of Cancer Immunotherapy market. Recent Changes and Development in Cancer Immunotherapy Market by Geography.

Read Full Details

Topics:
  • Business
  • Financial
News

Pfizer (NYSE:PFE) Given a $42.00 Price Target by Credit Suisse Group Analysts – Fairfield Current

PFE

Finally, Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, October 4th. The firm has a market capitalization of $275.20 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 2.30 and a beta of 0.88. Pfizer’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, analysts predict that Pfizer will post 3 EPS for the current fiscal year. In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of Pfizer stock in a transaction dated Monday, October 15th.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Global Sepsis Therapeutics Market 2019-2023 - Leading Players are Akorn, Baxter, Fresenius, Novartis, and Pfizer - ResearchAndMarkets.com

FRE PFE

Global Sepsis Therapeutics Market 2019-2023 - Leading Players are Akorn, Baxter, Fresenius, Novartis, and Pfizer - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Global Sepsis Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Global Sepsis Therapeutics Market is forecast to grow at a CAGR of 5.41% during the period 2019-2023. The global sepsis therapeutics market has an acute lack of approved therapies, resulting in huge unmet needs among sepsis patients and hampering the growth of the market.

Read Full Details

Topics:
  • Business
  • Health